BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 36759348)

  • 1. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
    Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
    Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis.
    Vázquez-Borrego MC; Del Río-Moreno M; Pyatkov M; Sarmento-Cabral A; Mahmood M; Pelke N; Wnek M; Cordoba-Chacon J; Waxman DJ; Puchowicz MA; McGuinness OP; Kineman RD
    Metabolism; 2023 Jul; 144():155589. PubMed ID: 37182789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
    Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
    Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose.
    Tian H; Fang Y; Liu W; Wang J; Zhao J; Tang H; Yin Y; Hu Y; Peng J
    J Ethnopharmacol; 2023 Jan; 301():115806. PubMed ID: 36216198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
    Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
    Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte glutathione peroxidase-1 deficiency improves hepatic glucose metabolism and decreases steatohepatitis in mice.
    Merry TL; Tran M; Dodd GT; Mangiafico SP; Wiede F; Kaur S; McLean CL; Andrikopoulos S; Tiganis T
    Diabetologia; 2016 Dec; 59(12):2632-2644. PubMed ID: 27628106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
    Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
    J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-32-5p induces hepatic steatosis and hyperlipidemia by triggering de novo lipogenesis.
    Wang YD; Wu LL; Mai YN; Wang K; Tang Y; Wang QY; Li JY; Jiang LY; Liao ZZ; Hu C; Wang YY; Liu JJ; Liu JH; Xiao XH
    Metabolism; 2023 Sep; 146():155660. PubMed ID: 37451670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity.
    Papadopoulos G; Legaki AI; Georgila K; Vorkas P; Giannousi E; Stamatakis G; Moustakas II; Petrocheilou M; Pyrina I; Gercken B; Kassi E; Chavakis T; Pateras IS; Panayotou G; Gika H; Samiotaki M; Eliopoulos AG; Chatzigeorgiou A
    Metabolism; 2023 Jul; 144():155552. PubMed ID: 36996933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
    Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
    Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor.
    Wang Z; Miu KK; Zhang X; Wan AT; Lu G; Cheung HH; Lee HM; Kong AP; Chan JC; Chan WY
    JHEP Rep; 2020 Dec; 2(6):100179. PubMed ID: 33134908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipocyte-specific deletion of Tcf7l2 induces dysregulated lipid metabolism and impairs glucose tolerance in mice.
    Nguyen-Tu MS; Martinez-Sanchez A; Leclerc I; Rutter GA; da Silva Xavier G
    Diabetologia; 2021 Jan; 64(1):129-141. PubMed ID: 33068125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis.
    Lee SR; Kwon SW; Kaya P; Lee YH; Lee JG; Kim G; Lee GS; Baek IJ; Hong EJ
    Sci Rep; 2018 Oct; 8(1):15711. PubMed ID: 30356113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte Kctd17 Inhibition Ameliorates Glucose Intolerance and Hepatic Steatosis Caused by Obesity-induced Chrebp Stabilization.
    Oh AR; Jeong Y; Yu J; Minh Tam DT; Kang JK; Jung YH; Im SS; Lee SB; Ryu D; Pajvani UB; Kim K
    Gastroenterology; 2023 Mar; 164(3):439-453. PubMed ID: 36402191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.